3,4-Dimethoxycarbonylcyclopentanon-ethylenketal | 36237-88-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3,4-Dimethoxycarbonylcyclopentanon-ethylenketal
• 英文别名: 1,4-dioxa-spiro[4.4]nonane-7,8-dicarboxylic acid dimethyl ester；Dimethyl 1,4-dioxaspiro[4.4]nonane-7,8-dicarboxylate
• CAS: 36237-88-4
• 化学式: C₁₁H₁₆O₆
• 分子量: 244.244
• InChiKey: GYIKGEVWDJACLQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  71.1
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3,4-Dimethoxycarbonylcyclopentanon-ethylenketal 生成 1,4-dioxaspiro[4.4]nonane-7,8-diyl dimethanol
  参考文献：
  名称：

  SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS

  摘要：

  The present disclosure provides certain sulfonamido derivatives that are Cyclin-dependent kinase 2 (CDK2) inhibitors of Formula (I): for the treatment of diseases treatable by inhibition of CDK2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  公开号：

  US20230303509A1
• 作为产物：
  描述：

  rac-4-oxocyclopentane-1,2-dicarboxylic acid 在 氯化亚砜 、 对甲苯磺酸 作用下， 以 甲苯 为溶剂， 反应 32.0h， 生成 3,4-Dimethoxycarbonylcyclopentanon-ethylenketal
  参考文献：
  名称：

  SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS

  摘要：

  The present disclosure provides certain sulfonamido derivatives that are Cyclin-dependent kinase 2 (CDK2) inhibitors of Formula (I): for the treatment of diseases treatable by inhibition of CDK2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  公开号：

  US20230303509A1

文献信息

• RIPK1抑制剂
  申请人：上海齐鲁制药研究中心有限公司

  公开号：CN116640156A

  公开（公告）日：2023-08-25

  本发明提供一类式(I)所示的具有RIPK1抑制活性的新型化合物，含有所述化合物的药物组合物、制备所述化合物的有用中间体以及利用本发明化合物治疗由RIPK1介导的相关疾病的方法。
• SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS
  申请人：NiKang Therapeutics, Inc.

  公开号：US20230303509A1

  公开（公告）日：2023-09-28

  The present disclosure provides certain sulfonamido derivatives that are Cyclin-dependent kinase 2 (CDK2) inhibitors of Formula (I): for the treatment of diseases treatable by inhibition of CDK2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.